Table 1

Association of HLA class II with clinical and immune parameters

CharacteristicsHLA class II on tumor cellsHLA class II on TILs
NegativePositiveP valueNegativePositiveP value
Age1.0000.133
 <7072 (91.1%)7 (8.9%)41 (51.9%)38 (48.1%)
 ≥7021 (91.3%)2 (8.7%)16 (69.6%)7 (30.4%)
Gender0.0800.622
 Female14 (77.9%)4 (22.2%)11 (61.1%)7 (38.9%)
 Male79 (94.1%)5 (5.9%)46 (54.8%)38 (45.2%)
Smoking status1.0000.065
 Non-smoker53 (91.4%)5 (8.6%)37 (63.8%)21 (36.2%)
 Smoker40 (90.9%)4 (9.1%)20 (45.5%)24 (54.5%)
T stage1.0000.051
 1–279 (90.8%)8 (9.2%)45 (51.7%)42 (48.3%)
 3–414 (93.3%)1 (6.7%)12 (80.0%)3 (20.0%)
N stage0.4940.002*
 039 (88.6%)5 (11.4%)17 (38.6%)27 (61.4%)
 1–254 (93.1%)4 (6.9%)40 (69.0%)18 (31.0%)
M stage1.0001.000
 089 (90.8%)9 (9.2%)55 (56.1%)43 (43.9%)
 14 (100.0%)0 (0.0%)2 (50.0%)2 (50.0%)
Lung cancer staging0.7330.066
 Stage I–II54 (90.0%)6 (10.0%)29 (48.3%)31 (51.7%)
 Stage III39 (92.9%)3 (7.1%)28 (66.7%)14 (33.3%)
PD-1 on TILs0.028*0.016*
 Negative59 (96.7%)2 (3.3%)40 (65.6%)21 (34.4%)
 Positive34 (82.9%)7 (17.1%)17 (41.5%)24 (58.5%)
PD-L1 on TILs1.000<0.001*
 Negative58 (90.6%)6 (9.4%)47 (73.4%)17 (26.6%)
 Positive35 (92.1%)3 (7.9%)10 (26.3%)28 (73.7%)
PD-L1 on tumor cells1.0000.318
 Negative89 (90.8%)9 (9.2%)56 (57.1%)42 (42.9%)
 Positive4 (100.0%)0 (0.0%)1 (25.0%)3 (75.0%)
CD30.495<0.001*
 Negative45 (93.7%)3 (6.3%)38 (79.2%)10 (20.8%)
 Positive48 (88.9%)6 (11.1%)19 (35.2%)35 (64.8%)
CD40.287<0.001*
 Negative60 (93.7%)4 (6.3%)45 (70.3%)19 (29.7%)
 Positive33 (86.8%)5 (13.2%)12 (31.6%)26 (68.4%)
CD80.466<0.001*
 Negative64 (92.8%)5 (7.2%)48 (69.6%)21 (30.4%)
 Positive29 (87.9%)4 (12.1%)9 (27.3%)24 (72.7%)
FOXP30.268<0.001*
 Negative63 (94.0%)4 (6.0%)49 (73.1%)18 (26.9%)
 Positive30 (85.7%)5 (14.3%)8 (22.9%)27 (77.1%)
  • *P<0.05 indicates statistical significance.

  • HLA class II, human leukocyte antigen class II; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; TILs, tumor infiltrating lymphocytes.